title: The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
abstract: This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD). Twenty-four patients with MSA-p and 26 cases with PD entered the study. They were submitted to treatments of clonidine, arginine and a combination of the two in a random manner on three different nonconsecutive days. The GH peak in serum at different times was evaluated and used as a primary variable for analysis of the stimulation test. By ROC analysis, we compared the sensitivity and specificity of tests of clonidine, arginine and both combined. After clonidine administration, the maximal average was significantly lower in patients with MSA-p than in those with PD (3.62 +/- 0.81 vs. 6.91 +/- 1.13; P < 0.05) with a sensitivity and specificity of 82.61 and 76.92%. After arginine administration, the maximal average GH concentration in serum at 30 min was also significantly lower in patients with MSA-p than in those with PD (4.07 +/- 0.80 vs. 7.89 +/- 1.29; P < 0.05) with a sensitivity and specificity of 78.26 and 73.08%. The sensitivity and specificity in differentiating MSA-p from PD was higher in the clonidine GH stimulation test than in the arginine GH stimulation test. However, when the clonidine and arginine were applied combined, the contrast of the maximal average GH concentration in serum in two groups was markedly increased (5.02 +/- 1.12 vs. 10.75 +/- 1.11; P < 0.05) with a sensitivity and specificity of 73.91 and 92.31%, and the specificity was notably increased in the combined GH stimulation test. Compared to the arginine GH stimulation test, the clonidine GH stimulation displayed a higher sensitivity and specificity; combined GH stimulation test of clonidine plus arginine could significantly enhance the specificity in differential diagnosis of MSA-p from PD.
authors.affiliation: Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Kezhong
authors.initials: K
authors.lastname: Zhang
authors.forename: Yanyin
authors.initials: Y
authors.lastname: Zeng
authors.forename: Chunjie
authors.initials: C
authors.lastname: Song
authors.forename: Yu
authors.initials: Y
authors.lastname: Fu
authors.forename: Qi
authors.initials: Q
authors.lastname: Wan
mesh_terms: D000368:Aged; D001120:Arginine / Q000008:administration & dosage; D003000:Clonidine / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004338:Drug Combinations; D005260:Female; D019382:Human Growth Hormone / Q000096:biosynthesis / Q000097:blood*; D006801:Humans; D008297:Male; D019578:Multiple System Atrophy / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology; D020734:Parkinsonian Disorders / Q000097:blood* / Q000175:diagnosis* / Q000473:pathology; D012680:Sensitivity and Specificity; D015854:Up-Regulation / Q000502:physiology
chemical_list: D004338:Drug Combinations; D019382:Human Growth Hormone; D001120:Arginine; D003000:Clonidine
references.citation: J Neurol Sci. 1979 Sep;43(1):59-82
references.pmid: 521829
references.citation: Clin Med Res. 2006 Dec;4(4):322-5
references.pmid: 17210980
references.citation: Muscle Nerve. 1997 Nov;20(11):1396-403
references.pmid: 9342156
references.citation: Neurology. 1999 Sep 22;53(5):1020-5
references.pmid: 10496261
references.citation: J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
references.pmid: 1564476
references.citation: J Neurol. 2000 Nov;247(11):853-6
references.pmid: 11151417
references.citation: Lancet. 1999 Apr 17;353(9161):1329-30
references.pmid: 10218537
references.citation: Mov Disord. 2002 Nov;17(6):1242-7
references.pmid: 12465063
references.citation: Ann Neurol. 1998 Feb;43(2):156-63
references.pmid: 9485056
references.citation: Mov Disord. 2008 Jan 30;23(2):190-4
references.pmid: 18044703
references.citation: Physiol Rev. 1999 Apr;79(2):511-607
references.pmid: 10221989
references.citation: J Neurol. 2002 Sep;249(9):1206-10
references.pmid: 12242540
references.citation: Mov Disord. 2000 Nov;15(6):1158-67
references.pmid: 11104200
references.citation: Neurology. 2000 Feb 8;54(3):697-702
references.pmid: 10680806
references.citation: Lancet. 1997 Jun 28;349(9069):1877-81
references.pmid: 9217760
references.citation: Mov Disord. 1999 May;14(3):430-5
references.pmid: 10348465
references.citation: Clin Endocrinol (Oxf). 2005 Apr;62(4):428-33
references.pmid: 15807873
references.citation: Endocr Rev. 1998 Dec;19(6):717-97
references.pmid: 9861545
references.citation: Arch Neurol. 1995 Mar;52(3):294-8
references.pmid: 7872884